- Actinogen Medical (ACW) finalises the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD)
- The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and depression
- The AD part B phase two trial will run for six months and is testing around 300 patients with results expected next year
- The MDD phase two trial will be a six week trial, testing around 120 patients, with results expected at the end of the year
- ACW shares are down 1.67 per cent on the market this afternoon to trade at 5.9 cents per share at market close
Actinogen Medical (ACW) has finalised the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD).
The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and depression.
Alzheimers Disease
The XanaMIA part B phase two trial will be a six-month dose-ranging, placebo-controlled trial.
It will be testing the drug on around 300 patients with early stage AD, including mild cognitive impairment patients.
The doses of Xanamem will be measured by the same cogstate cognitive test battery used in the part A trial.
Actinogen is expecting to receive results from the trial in 2024.
Major Depressive Disorder
The MDD phase two trial will be a six-week trial, testing around 120 patients with MDD and cognitive difficulties.
Xanamem will be added to exisiting anti-depressant therapy and effects on both depression and cognition will be assessed.
Results are expected in late 2023.
“We are now initiating two robust phase two trials in patients with Alzheimer’s Disease and Depression,” CEO Steven Gourlay said.
“Xanamem has the potential to be an effective low-dose daily oral therapy for these and many conditions where it may be used alone or in combination with other treatments.”
ACW shares were down 1.67 per cent on the market this afternoon to trade at 5.9 cents per share at market close.